PCM
FBIO icon

Pinz Capital Management’s Fortress Biotech FBIO Stock Holding History

Pinz Capital Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-380
Closed -$20K – 225
2021
Q2 		$20K Buy
+380
New +$22.9K 0.01% 360

Other funds holding FBIO

Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SAM
Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
CL
CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pinz Capital Management's FBIO Position: Q3 2021 in Review

Pinz Capital Management sold out of Fortress Biotech (FBIO) in Q3 2021, closing a stake of 380 shares — an estimated $20K sold.

Pinz Capital Management first reported a position in FBIO in Q2 2021 and held it in 1 quarter. The position peaked at $20K in Q2 2021. 79 funds tracked by Wall St. Rank hold FBIO as of Q3 2021.

  • Pinz Capital Management reported no remaining Fortress Biotech position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 380 Fortress Biotech shares in Q3 2021, an estimated $20K.
  • Pinz Capital Management first reported a position in Fortress Biotech in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Fortress Biotech position peaked at $20K in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.